When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor

J. Gill; V. Prasad

doi:10.1016/j.annonc.2019.11.021

When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor

J. Gill, V. Prasad

Knight Cancer Institute

Research output: Contribution to journal › Editorial › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	328-330
Number of pages	3
Journal	Annals of Oncology
Volume	31
Issue number	3
DOIs	https://doi.org/10.1016/j.annonc.2019.11.021
State	Published - Mar 2020

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.annonc.2019.11.021

Cite this

@article{535cb7aeb1cc4e8fa2d5ff9ef1a60c58,

title = "When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor",

author = "J. Gill and V. Prasad",

note = "Funding Information: VP receives royalties from his book Ending Medical Reversal , his work is funded by Arnold Ventures , he has received honoraria for Grand Rounds/lectures from several universities, medical centers, nonprofit groups, and professional societies, is a writer for Medscape and the host of the Plenary Session podcast, which receives crowdfunding support through the Patreon platform. JG declares no competing interests.",

year = "2020",

month = mar,

doi = "10.1016/j.annonc.2019.11.021",

language = "English (US)",

volume = "31",

pages = "328--330",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor

AU - Gill, J.

AU - Prasad, V.

N1 - Funding Information: VP receives royalties from his book Ending Medical Reversal , his work is funded by Arnold Ventures , he has received honoraria for Grand Rounds/lectures from several universities, medical centers, nonprofit groups, and professional societies, is a writer for Medscape and the host of the Plenary Session podcast, which receives crowdfunding support through the Patreon platform. JG declares no competing interests.

PY - 2020/3

Y1 - 2020/3

UR - http://www.scopus.com/inward/record.url?scp=85079395986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079395986&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2019.11.021

DO - 10.1016/j.annonc.2019.11.021

M3 - Editorial

C2 - 32067675

AN - SCOPUS:85079395986

SN - 0923-7534

VL - 31

SP - 328

EP - 330

JO - Annals of Oncology

JF - Annals of Oncology

IS - 3

ER -

When are randomized controlled trials needed to assess novel anticancer drugs? An illustration based on the development of selpercatinib, a RET inhibitor

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this